Abstract: Methods of treating tumors with preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as FGF2, or other ligand coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin or a prodrug-encoding agent. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.

Abstract: The present invention provides in situ bioreactors comprising a biocompatible substance comprising nucleic acid molecules and capable of cellular ingrowth and systemic delivery of a bioactive agent. Also provided are compositions, devices, and kits comprising the same. In various embodiments the biocompatible substance comprises a matrix and at least one nucleic acid molecule encoding a bioactive agent. In other embodiments bioreactors are provided wherein a first gene that encodes a growth factor is present and a second gene encoding a bioactive agent is present during manufacture or provided to the bioreactor following manufacture or implantation.